On Tuesday, Acumen Pharmaceuticals Inc (NASDAQ: ABOS) opened higher 7.74% from the last session, before settling in for the closing price of $1.55. Price fluctuations for ABOS have ranged from $0.86 to $3.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -54.87%. Company’s average yearly earnings per share was noted -16.92% at the time writing. With a float of $44.20 million, this company’s outstanding shares have now reached $60.57 million.
Considering the fact that the conglomerate employs 61 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Acumen Pharmaceuticals Inc (ABOS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Acumen Pharmaceuticals Inc is 27.03%, while institutional ownership is 58.48%. The most recent insider transaction that took place on Jan 23 ’25, was worth 49,633. In this transaction CFO & Chief Business Officer of this company sold 28,902 shares at a rate of $1.72, taking the stock ownership to the 231,744 shares. Before that another transaction happened on Jan 21 ’25, when Company’s CFO & Chief Business Officer sold 4,364 for $1.60, making the entire transaction worth $6,986. This insider now owns 260,646 shares in total.
Acumen Pharmaceuticals Inc (ABOS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.52 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.29% during the next five years compared to -54.87% drop over the previous five years of trading.
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Trading Performance Indicators
Check out the current performance indicators for Acumen Pharmaceuticals Inc (ABOS). In the past quarter, the stock posted a quick ratio of 8.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.93, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Acumen Pharmaceuticals Inc (ABOS)
Compared to the last year’s volume of 0.34 million, its volume of 0.5 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 88.43%.
During the past 100 days, Acumen Pharmaceuticals Inc’s (ABOS) raw stochastic average was set at 95.32%, which indicates a significant increase from 93.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1040 in the past 14 days, which was higher than the 0.0919 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1748, while its 200-day Moving Average is $1.6203. Nevertheless, the first resistance level for the watch stands at $1.7367 in the near term. At $1.8033, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8967. If the price goes on to break the first support level at $1.5767, it is likely to go to the next support level at $1.4833. Should the price break the second support level, the third support level stands at $1.4167.
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Key Stats
There are currently 60,573K shares outstanding in the company with a market cap of 101.16 million. Presently, the company’s annual sales total 0 K according to its annual income of -102,330 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -28,800 K.
